Literature DB >> 34088969

RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.

Haiwei Wang1,2, Xinrui Wang3,4, Ji Zhang5, Liangpu Xu3,4, Hua Cao6,7.   

Abstract

Based on isocitrate dehydrogenase (IDH) alterations, lower grade glioma (LGG) is divided into IDH mutant and wild type subgroups. However, the further classification of IDH wild type LGG was unclear. Here, IDH wild type LGG patients in The Cancer Genome Atlas and Chinese Glioma Genome Atlas were divided into two sub-clusters using non-negative matrix factorization. IDH wild type LGG patients in sub-cluster2 had prolonged overall survival and low frequency of CDKN2A alterations and low immune infiltrations. Differentially expressed genes in sub-cluster1 were positively correlated with RUNX1 transcription factor. Moreover, IDH wild type LGG patients with higher stromal score or immune score were positively correlated with RUNX1 transcription factor. RUNX1 and its target gene REXO2 were up-regulated in sub-cluster1 and associated with the worse prognosis of IDH wild type LGG. RUNX1 and REXO2 were associated with the higher immune infiltrations. Furthermore, RUNX1 and REXO2 were correlated with the worse prognosis of LGG or glioma. IDH wild type LGG in sub-cluster2 was hyper-methylated. REXO2 hyper-methylation was associated with the favorable prognosis of LGG or glioma. At last, we showed that, age, tumor grade and REXO2 expression were independent prognostic factors in IDH wild type LGG.

Entities:  

Year:  2021        PMID: 34088969     DOI: 10.1038/s41598-021-91382-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  46 in total

1.  Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.

Authors:  Sevin Turcan; Vladimir Makarov; Julian Taranda; Yuxiang Wang; Armida W M Fabius; Wei Wu; Yupeng Zheng; Nour El-Amine; Sara Haddock; Gouri Nanjangud; H Carl LeKaye; Cameron Brennan; Justin Cross; Jason T Huse; Neil L Kelleher; Pavel Osten; Craig B Thompson; Timothy A Chan
Journal:  Nat Genet       Date:  2017-11-27       Impact factor: 38.330

2.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Authors:  Chao Lu; Patrick S Ward; Gurpreet S Kapoor; Dan Rohle; Sevin Turcan; Omar Abdel-Wahab; Christopher R Edwards; Raya Khanin; Maria E Figueroa; Ari Melnick; Kathryn E Wellen; Donald M O'Rourke; Shelley L Berger; Timothy A Chan; Ross L Levine; Ingo K Mellinghoff; Craig B Thompson
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.

Authors:  Andrea E Calvert; Alexandra Chalastanis; Yongfei Wu; Lisa A Hurley; Fotini M Kouri; Yingtao Bi; Maureen Kachman; Jasmine L May; Elizabeth Bartom; Youjia Hua; Rama K Mishra; Gary E Schiltz; Oleksii Dubrovskyi; Andrew P Mazar; Marcus E Peter; Hongwu Zheng; C David James; Charles F Burant; Navdeep S Chandel; Ramana V Davuluri; Craig Horbinski; Alexander H Stegh
Journal:  Cell Rep       Date:  2017-05-30       Impact factor: 9.423

6.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

7.  A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.

Authors:  Christopher G Duncan; Benjamin G Barwick; Genglin Jin; Carlo Rago; Priya Kapoor-Vazirani; Doris R Powell; Jen-Tsan Chi; Darell D Bigner; Paula M Vertino; Hai Yan
Journal:  Genome Res       Date:  2012-08-16       Impact factor: 9.043

8.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2010-06-17       Impact factor: 69.504

9.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

10.  Mutant IDH1 Promotes Glioma Formation In Vivo.

Authors:  Beatrice Philip; Diana X Yu; Mark R Silvis; Clifford H Shin; James P Robinson; Gemma L Robinson; Adam E Welker; Stephanie N Angel; Sheryl R Tripp; Joshua A Sonnen; Matthew W VanBrocklin; Richard J Gibbons; Ryan E Looper; Howard Colman; Sheri L Holmen
Journal:  Cell Rep       Date:  2018-05-01       Impact factor: 9.423

View more
  2 in total

1.  PBX1, EMCN and ERG are associated with the sub-clusters and the prognosis of VHL mutant clear cell renal cell carcinoma.

Authors:  Haiwei Wang; Xinrui Wang; Liangpu Xu; Ji Zhang
Journal:  Sci Rep       Date:  2022-05-27       Impact factor: 4.996

2.  Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.

Authors:  Yudong Cao; Hecheng Zhu; Quan Chen; Hailong Huang; Dongcheng Xie; Xuewen Li; Xingjun Jiang; Caiping Ren; Jiahui Peng
Journal:  Front Pharmacol       Date:  2022-08-26       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.